Rayan Alkhodair, Yazeed Alowairdhi, Abdulrahman Alfawzan, Ali Alghamdi
{"title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in Saudi Arabia: a retrospective cross-sectional multicenter study.","authors":"Rayan Alkhodair, Yazeed Alowairdhi, Abdulrahman Alfawzan, Ali Alghamdi","doi":"10.4081/dr.2025.10275","DOIUrl":"https://doi.org/10.4081/dr.2025.10275","url":null,"abstract":"<p><p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are a spectrum of life-threatening mucocutaneous conditions. Despite having a lower incidence rate than other dermatological conditions, SJS/TEN has a high mortality rate. SJS/TEN is usually caused by newly administered medications, particularly antibacterials and anticonvulsants. Little research data on SJS/TEN in Saudi Arabia has been published. We aimed to bridge this gap by reviewing and investigating the etiologies, risk factors, interventions, and outcomes of patients diagnosed with SJS/TEN. This is a retrospective cross-sectional study conducted in National Guard Hospitals in Riyadh and Jeddah from January 2015 to July 2023. We reviewed all dermatology medical records diagnosed as SJS/TEN through clinical assessment and histopathology, confirmed by a dermatology consultant. Additionally, we excluded all non-Saudi patients and those referred to our center with outside reports without histopathology from the national guard hospitals. This study included 25 patients diagnosed with the SJS/TEN spectrum between January 2015 and July 2023. Nearly two-thirds of the patients were male (n=15, 60%), and the average age was 45.96 years. Almost half of the culprit agents were antibiotics. Six of the 25 patients died (24%). Four were males, all over 50 years old, and one female was 6 years old. All these patients had TEN, except for one with SJS. Septic shock was the cause of death in 4 patients. Given the evident high risk for patients contracting this condition, prospective research and analysis to understand the correlation between SJS/TEN, mortality, and treatment are warranted.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction: <i>Diagnosis and epidemiologic overview of the spectrum of skin diseases in Central, Northeast, and Southern Ethiopia</i>.","authors":"The Publisher","doi":"10.4081/dr.2025.10530","DOIUrl":"10.4081/dr.2025.10530","url":null,"abstract":"<p><p>In the published Article titled \"Diagnosis and epidemiologic overview of the spectrum of skin diseases in Central, Northeast, and Southern Ethiopia\" (DOI: 10.4081/dr.2024.10114), the order of the authors was incorrect, and the 10th author (Frehiwot Daba) was mistakenly omitted.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"17 2","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Filomena Barbato, Maria Maddalena Nicoletti, Gaetano Licata, Eugenia Veronica Di Brizzi, Giuseppe Argenziano, Caterina Mariarosaria Giorgio
{"title":"Dermoscopy of kaposiform hemangioendothelioma: a case report.","authors":"Filomena Barbato, Maria Maddalena Nicoletti, Gaetano Licata, Eugenia Veronica Di Brizzi, Giuseppe Argenziano, Caterina Mariarosaria Giorgio","doi":"10.4081/dr.2025.10363","DOIUrl":"https://doi.org/10.4081/dr.2025.10363","url":null,"abstract":"<p><p>Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor of infancy, characterized by an infiltrative, firm, and ill-defined plaque that may be associated with Kasabach-Merritt phenomenon. While the diagnosis is primarily clinical and histopathological, dermoscopy may provide valuable insights into its microstructural features. We present the case of a newborn with congenital KHE involving the lumbar and right gluteal region, focusing on its dermoscopic characteristics. The lesion exhibited a homogeneous, grayish-blue background with no discernible vascular structures, a feature that may aid in differentiating KHE from other vascular tumors. The findings contribute to the understanding of dermoscopic patterns in KHE, highlighting its potential role in early diagnosis.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thilo Gambichler, Sera Selina Weyer-Fahlbusch, Markus Werner, Ulrika Schade, Lieselotte Bissels, Laura Susok
{"title":"Primary cutaneous marginal zone lymphoma in a patient with multiple sclerosis under fingolimod therapy.","authors":"Thilo Gambichler, Sera Selina Weyer-Fahlbusch, Markus Werner, Ulrika Schade, Lieselotte Bissels, Laura Susok","doi":"10.4081/dr.2025.10237","DOIUrl":"https://doi.org/10.4081/dr.2025.10237","url":null,"abstract":"<p><p>Dear Editor, Increased prevalence of cancer, in particular lymphomas, has been observed in patients with multiple sclerosis (MS) treated with fingolimod. We report the first case of primary cutaneous marginal zone lymphoma (PCMZL) that developed under long-term fingolimod therapy for MS. [...].</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Simone Amato, Annunziata Dattola, Luigi Bennardo, Martina Tolone, Steven Paul Nisticò
{"title":"Efficacy of a topical polyphenol-based formulation in palmoplantar psoriasis: an observational study.","authors":"Simone Amato, Annunziata Dattola, Luigi Bennardo, Martina Tolone, Steven Paul Nisticò","doi":"10.4081/dr.2025.10333","DOIUrl":"https://doi.org/10.4081/dr.2025.10333","url":null,"abstract":"<p><p>This single-arm observational study evaluated the efficacy and safety of a novel topical formulation containing a complex mixture of polyphenols (CMP) - a proprietary blend rich in oleocanthal and oleuropein aglycone (each >60%), along with hydroxytyrosol and other extra virgin olive oil (EVOO)-derived polyphenols - combined with triticum vulgare germ (TVG) oil, betaine, propanediol, and tocopheryl acetate in patients with mild palmoplantar psoriasis (PPP). Twenty participants (aged 20-55) applied the formulation twice daily for 8 days, with assessments conducted on days 0 (baseline), 5, and 8. Participants underwent a 60-day follow-up to assess the durability of benefits and potential late-onset adverse events. Clinical evaluations measured lesion extent, keratinization, inflammation, desquamation, and infiltration. A patient-reported questionnaire evaluated quality of life (QoL) and symptom burden. By day 8, the mean lesion extent had decreased by approximately 40%, inflammation had improved by about 50%, and desquamation had resolved fully in most cases. Patient-reported outcomes improve alongside clinical measures. At day 60, these improvements persisted in 85% of participants, and no adverse events emerged. The formulation's mechanism of action is hypothesized to involve the concerted antioxidant and anti-inflammatory activities of polyphenols (oleocanthal, oleuropein aglycone, and hydroxytyrosol) in synergy with TVG oil's supportive lipid matrix and other excipients. These findings suggest that EVOO-derived polyphenols formulated in TVG oil may serve as a valuable adjunct for managing PPP with good tolerability and sustained benefits.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Purpura following laser hair removal: a case report.","authors":"Kalliopi Papadopoulou, Eleni Paschalidou, Despoina Kosta, Kalliopi Karamanolaki","doi":"10.4081/dr.2025.10295","DOIUrl":"https://doi.org/10.4081/dr.2025.10295","url":null,"abstract":"<p><p>Laser hair removal (LHR) is a reliable and safe technique for the long-term reduction of unwanted hair. Common adverse effects involve momentary discomfort, transient erythema, and perifollicular edema, while the occurrence of purpura is infrequent. A 25-year-old Greek woman with skin type IV developed purpura on her lower extremities 48 hours after her first alexandrite laser session. A positive response to a laser hair removal provocation test was identified, aiding in diagnosis. Treatment with orally administered corticosteroids and antihistamines led to complete resolution within 7 days. Purpura following laser hair removal is a rare side effect, and its underlying cause remains unclear. Physician awareness of such adverse reactions can streamline patient care, reducing the need for unnecessary tests and offering improved management protocols.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elena Pezzolo, Sara Di Leo, Paola Miceli, Alvise Sernicola, Luigi Naldi
{"title":"The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review.","authors":"Elena Pezzolo, Sara Di Leo, Paola Miceli, Alvise Sernicola, Luigi Naldi","doi":"10.4081/dr.2025.10112","DOIUrl":"https://doi.org/10.4081/dr.2025.10112","url":null,"abstract":"<p><p>Mesenchymal stem cell (MSC) therapy holds promise for treating immune-mediated inflammatory skin diseases (IMIDs), particularly when conventional therapies are ineffective. Encouraged by their immunomodulatory capabilities and potential for disease modification, different clinical trials are investigating the efficacy and safety of MSCs in single IMIDs. This review aims to summarize the application of MSCs in IMIDs and explore their future clinical potential. We reviewed published studies from January 2016 to January 2024 on MSC treatment for IMIDs. We retrieved 18 clinical trials and 5 observational studies, encompassing 609 patients with psoriasis, atopic dermatitis (AD), chronic spontaneous urticaria (CSU), alopecia areata (AA), systemic sclerosis (SSc), and systemic lupus erythematosus (SLE). Improvements or complete remission were observed in up to 100% of cases for AA, SSc, and SLE, though complete remission rates were less frequent than improvement rates, ranging from 0% in AD to 50% in CSU. Adverse events (AEs) were generally mild; moderate-to-severe AEs were uncommon (4% in psoriasis, 2.6% in SLE, and 0.7% in SSc), and deaths from all causes were rare (6 patients with SSc and 15 patients with SLE). In conclusion, MSC therapy shows promising results in terms of at least partial clinical improvement for most IMIDs. Its effect is achievable after a single or a few administrations, with no significant toxicity. MSCs may fulfill an unmet need for patients unresponsive to conventional immunomodulating agents. However, most evidence still comes from clinical trials with heterogeneous designs and endpoints. Future larger controlled trials are needed to better elucidate their role in refractory IMIDs.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti
{"title":"Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy.","authors":"Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti","doi":"10.4081/dr.2025.10315","DOIUrl":"https://doi.org/10.4081/dr.2025.10315","url":null,"abstract":"<p><p>Adalimumab (ADA), a monoclonal antibody targeting TNF-α, is effective in treating moderate to severe psoriasis. The emergence of biosimilars, such as GP2017 (Hyrimoz®), has raised concerns about their safety and efficacy compared to the originator. This two-year observational study evaluated the effectiveness and safety of GP2017 in 171 patients from Emilia-Romagna, Italy. Patients were divided into two groups: 78 transitioned from the ADA originator, and 93 were biologic-naive. Changes in the Psoriasis Area and Severity Index (PASI) were analyzed. In the switch group, PASI scores remained stable, while the naive group achieved significant improvements (PASI 75: 52% at 3 months, 89% at 6 months). Adverse events leading to discontinuation were rare. The findings confirm that GP2017 is as effective and safe as the ADA originator, supporting its use as a cost-effective alternative in the treatment of psoriasis. Biosimilars play a crucial role in promoting equitable access to biologic therapies.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carlotta Bertolina, Marinella Bertolotti, Claudia Leporati, Antonina Maria De Angelis, Sara Delfanti, Luigi Cerbone, Marco Ghiglione, Federica Grosso
{"title":"Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report.","authors":"Carlotta Bertolina, Marinella Bertolotti, Claudia Leporati, Antonina Maria De Angelis, Sara Delfanti, Luigi Cerbone, Marco Ghiglione, Federica Grosso","doi":"10.4081/dr.2025.10324","DOIUrl":"https://doi.org/10.4081/dr.2025.10324","url":null,"abstract":"<p><p>Here we report the case of a woman suffering from advanced melanoma who developed severe toxicities with BRAF and MEK inhibitors (BRAFis, MEKis), given as second-line therapy after failure of immunotherapy, who achieved a complete and durable response lasting for over 5 years. Significant progress has been achieved in the treatment of advanced melanoma with immune checkpoint inhibitors (ICIs) and targeted therapies using BRAFis and MEKis. While these treatments improve survival, they also pose risks of severe toxicities. Notably, when targeted therapy follows immunotherapy, immune-mediated toxicities may emerge months later due to tumor microenvironment modulation. Despite these risks, both approaches offer a durable response in eligible patients. Further understanding is needed to determine how prior immunotherapy may influence subsequent toxicity risks of target therapy. Understanding these factors could optimize treatment strategies and improve patient outcomes.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Caterina Mariarosaria Giorgio, Gaetano Licata, Maria Maddalena Nicoletti, Eugenia Veronica Di Brizzi, Vittorio Tancredi, Giuseppe Argenziano, Valentina Cozza, Adone Baroni
{"title":"Post-COVID-19 resurgence of scabies in Campania, Italy: the hidden burden and challenges in surveillance.","authors":"Caterina Mariarosaria Giorgio, Gaetano Licata, Maria Maddalena Nicoletti, Eugenia Veronica Di Brizzi, Vittorio Tancredi, Giuseppe Argenziano, Valentina Cozza, Adone Baroni","doi":"10.4081/dr.2025.10409","DOIUrl":"https://doi.org/10.4081/dr.2025.10409","url":null,"abstract":"<p><p>Scabies, a contagious parasitic skin disease caused by Sarcoptes scabiei, has shown a marked resurgence in several European regions following the COVID-19 pandemic. In Campania, Italy, reported cases increased from 42 in 2020 to 748 in 2024, according to the regional surveillance system (Sistema Premal-UOD). However, the true burden of disease is likely underestimated due to widespread underreporting, delayed diagnosis, and a hidden reservoir of undetected or self-treated cases. This study analyzes epidemiological trends in Campania, highlights limitations in surveillance, and examines the role of pseudo-resistance in treatment failures. The findings underscore the need for robust monitoring, accurate diagnostics, and public health interventions to reduce the ongoing spread of scabies in the region.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}